Skip to content

Investor Relations / Recent Updates

Recent Updates

To see the most recent information published for each of the categories below click the header of the box.

Latest Peer-Reviewed Reprints
 

Nichols GA, Philip S, Reynolds K, Granowitz CB, O’Keeffe-Rosetti M, Fazio S. Comparison of medical care utilization and costs among patients with statin-controlled LDL cholesterol with versus without hypertriglyceridemia. Am J Cardiol. 2018. Doi: 10.1016/j.amjcard.2018.06.029. (epub of accepted version)
https://www.ajconline.org/article/S0002-9149(18)31321-3/fulltext

 

Toth PP, Granowitz C, Hull M, Liassou D, Anderson A, Philip S. High triglycerides are associated with increased cardiovascular events, medical costs, and resource use: A real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk. J Am Heart Assoc. 2018;7(15):e008740. (epub)
Free:
https://www.ahajournals.org/doi/10.1161/JAHA.118.008740

 

Nichols GA, Philip S, Reynolds K, Granowitz CB, Fazio S. Increased cardiovascular risk in hypertriglyceridemic patients with statin-controlled LDL cholesterol. J Clin Endocrinol Metab. 2018 (epub ahead of print).
Free:
https://doi.org/10.1210/jc.2018-00470

 

Latest SEC Filings

Filing date Form View
6-K View HTML
S-8 View HTML
6-K View HTML
copyright
© 2018, Amarin Corporation
Privacy policy  |  Disclaimer
Dublin Office
2 Pembroke House, Upper Pembroke
Street 28-32
Dublin 2, Ireland
US Investor Relations
Amarin Pharma Inc.
1430 Route 206
Bedminster, NJ 07921 USA
Telephone:
+1 908 719 1315
Fax:
+1 908 719 3012

Amarin Corporation